Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis-Reference-Cited by-同舟云学术

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis

Published:2018-12-21 Issue:1 Volume:8 Page:137-146
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Hiraoka Atsushi¹^ORCID,Kumada Takashi²,Kariyama Kazuya³,Takaguchi Koichi⁴,Atsukawa Masanori⁵,Itobayashi Ei⁶,Tsuji Kunihiko⁷,Tajiri Kazuto⁸,Hirooka Masashi⁹,Shimada Noritomo¹⁰,Shibata Hiroshi¹¹,Ishikawa Toru¹²,Ochi Hironori¹³,Tada Toshifumi²,Toyoda Hidenori²^ORCID,Nouso Kazuhiro³,Tsutsui Akemi⁴,Itokawa Norio⁵,Imai Michitaka¹²,Joko Kouji¹³,Hiasa Yoichi⁹,Michitaka Kojiro¹,

Affiliation:

1. Gastroenterology Center; Ehime Prefectural Central Hospital; Matsuyama Japan

2. Department of Gastroenterology and Hepatology; Ogaki Municipal Hospital; Gifu Japan

3. Department of Gastroenterology; Okayama City Hospital; Okayama Japan

4. Department of Hepatology; Kagawa Prefectural Central Hospital; Takamatsu Japan

5. Division of Gastroenterology and Hepatology, Department of Internal Medicine; Nippon Medical School; Tokyo Japan

6. Department of Gastroenterology; Asahi General Hospital; Asahi Japan

7. Center of Gastroenterology; Teine Keijinkai Hospital; Sapporo Japan

8. Department of Gastroenterology; Toyama University Hospital; Toyama Japan

9. Department of Gastroenterology and Metabology; Ehime University Graduate School of Medicine; Toon Japan

10. Division of Gastroenterology and Hepatology; Otakanomori Hospital; Kashiwa Japan

11. Department of Gastroenterology; Tokushima Prefectural Central Hospital; Tokushima Japan

12. Department of Gastroenterology; Saiseikai Niigata Daini Hospital; Niigata Japan

13. Hepato-biliary Center; Matsuyama Red Cross Hospital; Matsuyama Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1909/fullpdf

Reference45 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017

4. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial;Finn;J Hepatol,2018

5. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma;Ikeda;J Gastroenterol,2017

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study;European Journal of Gastroenterology & Hepatology;2024-01

2. Pyroptosis: the dawn of a new era in endometrial cancer treatment;Frontiers in Oncology;2023-10-30

3. Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib;2023-10-24

4. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence;Current Oncology;2023-09-26

5. Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case report;Oncology Letters;2023-08-31